Ketamine topical formulation - Psycheceutical
Alternative Names: NeuroDirect™ topical formulation ketamine - psycheceuticalLatest Information Update: 28 Apr 2026
At a glance
- Originator Psycheceutical
- Class Amines; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Ketones; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Post-traumatic stress disorders
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for clinical-Phase-Unknown development in Post-traumatic-stress-disorders in Unknown (Topical)
- 27 Jul 2023 Chemical structure information added
- 29 Mar 2023 Psycheceutical in collaboration wit iNGENu plans a phase I trial for post-traumatic stress disorder (In volunteers, In adults) in Australia (Topical) in the second quarter of 2023